To test whether AT2‑derived lipids are required for metastasis, the researchers selectively deleted Fasn in AT2 cells.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

Company Served as Sponsor and Provided Operational Leadership for Study Conducted in Partnership with TGen and Virta ...

SAN FRANCISCO — Maintenance treatment with capecitabine (Xeloda) and bevacizumab (Avastin) significantly delayed disease progression, compared with observation, in patients with metastatic colorectal ...

When you have HR+/HER2– metastatic breast cancer, a big part of treatment includes monitoring the condition with routine scans, physical exams, and blood tests. But the type of testing you’ll need — ...

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Forkhead Box Q1 (FOXQ1) is a pivotal transcription factor that has attracted significant attention for its roles in regulating cancer metastasis and progression. Research indicates that FOXQ1 ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan ...